Leveraging Genetics to Advance Type 2 Diabetes Prevention


In this Perspective, Jose Florez discusses how information from genetics and genomics may be able to contribute to prevention of type 2 diabetes and predicting individual responses to behavioral and other interventions.


Vyšlo v časopise: Leveraging Genetics to Advance Type 2 Diabetes Prevention. PLoS Med 13(7): e32767. doi:10.1371/journal.pmed.1002102
Kategorie: Perspective
prolekare.web.journal.doi_sk: 10.1371/journal.pmed.1002102

Souhrn

In this Perspective, Jose Florez discusses how information from genetics and genomics may be able to contribute to prevention of type 2 diabetes and predicting individual responses to behavioral and other interventions.


Zdroje

1. International Diabetes Federation. IDF Diabetes Atlas. 7 ed: International Diabetes Federation; 2015.

2. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537–544. 9096977.

3. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–1350. 11333990.

4. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. 11832527.

5. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–297. 16391903.

6. Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, et al. Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the Diabetes Prevention Program. Diabetes. 2011;60(4):1340–1348. 21378175; PubMed Central PMCID: PMC3064108. doi: 10.2337/db10-1119.

7. Hivert MF, Christophi CA, Franks PW, Jablonski KA, Ehrmann DA, Kahn SE, et al. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes. 2016;65(2):520–526. Epub 2015/11/04. doi: 10.2337/db15-0950 26525880; PubMed Central PMCID: PMC4747453.

8. Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2(6):474–480. Epub 2014/04/16. doi: 10.1016/s2213-8587(14)70057-9 24731674.

9. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–1686. Epub 2009/11/03. doi: 10.1016/s0140-6736(09)61457-4 19878986; PubMed Central PMCID: PMC3135022.

10. Herman WH, Edelstein SL, Ratner RE, Montez MG, Ackermann RT, Orchard TJ, et al. Effectiveness and cost-effectiveness of diabetes prevention among adherent participants. Am J Manag Care. 2013;19(3):194–202. Epub 2013/04/03. 23544761; PubMed Central PMCID: PMC3985133.

11. Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the Diabetes Prevention Program. Diabetes. 2010;59(10):2672–2681. Epub 2010/08/05. doi: 10.2337/db10-0543 20682687; PubMed Central PMCID: PMC3279522.

12. Mohlke KL, Boehnke M. Recent advances in understanding the genetic architecture of type 2 diabetes. Hum Mol Genet. 2015;24(R1):R85–92. doi: 10.1093/hmg/ddv264 26160912; PubMed Central PMCID: PMC4572004.

13. Estrada K, Aukrust I, Bjorkhaug L, Burtt NP, Mercader JM, Garcia-Ortiz H, et al. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA. 2014;311(22):2305–2314. Epub 2014/06/11. doi: 10.1001/jama.2014.6511 24915262; PubMed Central PMCID: PMC4425850.

14. Moltke I, Grarup N, Jorgensen ME, Bjerregaard P, Treebak JT, Fumagalli M, et al. A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Nature. 2014;512(7513):190–193. doi: 10.1038/nature13425 25043022.

15. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359(21):2208–2219. 19020323; PubMed Central PMCID: PMC2746946. doi: 10.1056/NEJMoa0804742.

16. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359(21):2220–2232. 19020324. doi: 10.1056/NEJMoa0801869.

17. Vassy JL, Hivert MF, Porneala B, Dauriz M, Florez JC, Dupuis J, et al. Polygenic type 2 diabetes prediction at the limit of common variant detection. Diabetes. 2014;63(6):2172–2182. Epub 2014/02/13. doi: 10.2337/db13-1663 24520119; PubMed Central PMCID: PMC4030114.

18. Walford GA, Porneala BC, Dauriz M, Vassy JL, Cheng S, Rhee EP, et al. Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes. Diabetes Care. 2014;37(9):2508–2514. Epub 2014/06/21. doi: 10.2337/dc14-0560 24947790; PubMed Central PMCID: PMC4140156.

19. Langenberg C, Sharp SJ, Franks PW, Scott RA, Deloukas P, Forouhi NG, et al. Gene-lifestyle interaction and type 2 diabetes: the EPIC interact case-cohort study. PLoS Med. 2014;11(5):e1001647. Epub 2014/05/23. doi: 10.1371/journal.pmed.1001647 24845081; PubMed Central PMCID: PMC4028183.

20. Pan Q, Delahanty LM, Jablonski KA, Knowler WC, Kahn SE, Florez JC, et al. Variation at the melanocortin 4 receptor gene and response to weight-loss interventions in the Diabetes Prevention Program. Obesity (Silver Spring). 2013;21(9):E520–526. doi: 10.1002/oby.20459 23512951.

21. Pollin TI, Jablonski KA, McAteer JB, Saxena R, Kathiresan S, Kahn SE, et al. Triglyceride response to an intensive lifestyle intervention is enhanced in carriers of the GCKR Pro446Leu polymorphism. J Clin Endocrinol Metab. 2011;96(7):E1142–E1147. 21525158; PubMed Central PMCID: PMC3205512. doi: 10.1210/jc.2010-2324.

22. Pollin TI, Isakova T, Jablonski KA, de Bakker PI, Taylor A, McAteer J, et al. Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: The Diabetes Prevention Program. PLoS Genet. 2012;8(8):e1002895. 22951888; PubMed Central PMCID: PMC3431328.

23. Papandonatos GD, Pan Q, Pajewski NM, Delahanty LM, Peter I, Erar B, et al. Genetic predisposition to weight loss and regain with lifestyle intervention: Analyses from the Diabetes Prevention Program and the Look AHEAD randomized controlled trials. Diabetes. 2015;64(12):4312–4321. Epub 2015/08/09. doi: 10.2337/db15-0441 26253612; PubMed Central PMCID: PMC4657576.

24. Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study. Diabetes. 2009;58(3):745–749. doi: 10.2337/db08-1028 19228809.

25. Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2011;43(2):117–120. Epub 2010/12/28. ng.735 [pii] doi: 10.1038/ng.735 21186350; PubMed Central PMCID: PMC3030919.

26. Florez JC, Jablonski KA, Taylor A, Mather K, Horton E, White NH, et al. The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care. 2012;35(9):1864–1867. 22751958; PubMed Central PMCID: PMC3425006.

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2016 Číslo 7
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Eozinofilní granulomatóza s polyangiitidou
nový kurz

Betablokátory a Ca antagonisté z jiného úhlu
Autori: prof. MUDr. Michal Vrablík, Ph.D., MUDr. Petr Janský

Autori: doc. MUDr. Petr Čáp, Ph.D.

Farmakoterapie akutní a chronické bolesti

Získaná hemofilie - Povědomí o nemoci a její diagnostika

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Nemáte účet?  Registrujte sa

Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa